Stereotactic body radiation therapy for stage I non-small cell lung cancer
- PMID: 17626403
- DOI: 10.1016/j.thorsurg.2007.03.011
Stereotactic body radiation therapy for stage I non-small cell lung cancer
Abstract
Image-guided SBRT with the delivery of a BED greater than 100 Gy is feasible and safe in the treatment of peripherally located inoperable stage I NSCLC. The 3- to 5-year local control and overall survival rates for SBRT seem to be much better than the rates for conventional radiotherapy, and the toxicity rate is minimal. Particularly for stage Ia (T1N0M0) disease, survival rates with SBRT were comparable with rates seen with surgical resection. SBRT is becoming the standard treatment for inoperable stage I NSCLC. Its role in operable stage I NSCLC. however. is not clear. To balance improved targeting accuracy with minimized treatment-related toxicity. a reliable immobilization device and consideration of image-guided tumor motion are crucial. The optimal dose regimen remains unclear, but a BED greater than 100 Gy seems warranted.
Similar articles
-
Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.Discov Med. 2010 May;9(48):411-7. Discov Med. 2010. PMID: 20515609 Review.
-
Stereotactic body radiation therapy (SBRT) for early-stage lung cancer.Cancer Radiother. 2007 Jan-Feb;11(1-2):32-5. doi: 10.1016/j.canrad.2006.11.001. Epub 2006 Dec 8. Cancer Radiother. 2007. PMID: 17158081
-
Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):964-73. doi: 10.1016/j.ijrobp.2010.06.040. Epub 2010 Oct 6. Int J Radiat Oncol Biol Phys. 2011. PMID: 20932688
-
Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):117-25. doi: 10.1016/j.ijrobp.2006.04.013. Epub 2006 Jun 9. Int J Radiat Oncol Biol Phys. 2006. PMID: 16765528
-
Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.Cancer Treat Rev. 2008 Dec;34(8):719-27. doi: 10.1016/j.ctrv.2008.06.001. Epub 2008 Jul 26. Cancer Treat Rev. 2008. PMID: 18657910 Review.
Cited by
-
Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team.Cancers (Basel). 2011 Sep 1;3(3):3432-48. doi: 10.3390/cancers3033432. Cancers (Basel). 2011. PMID: 24212962 Free PMC article.
-
A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer.Support Care Cancer. 2013 Jan;21(1):211-8. doi: 10.1007/s00520-012-1513-9. Epub 2012 Jun 2. Support Care Cancer. 2013. PMID: 22661073
-
Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.J Radiat Res. 2016 Sep;57(5):533-540. doi: 10.1093/jrr/rrw045. Epub 2016 Jun 13. J Radiat Res. 2016. PMID: 27296251 Free PMC article.
-
Patient-clinician communication among patients with stage I lung cancer.Support Care Cancer. 2018 May;26(5):1625-1633. doi: 10.1007/s00520-017-3992-1. Epub 2017 Dec 5. Support Care Cancer. 2018. PMID: 29209835 Clinical Trial.
-
Improving radiation conformality in the treatment of non-small cell lung cancer.Semin Radiat Oncol. 2010 Jul;20(3):171-7. doi: 10.1016/j.semradonc.2010.01.005. Semin Radiat Oncol. 2010. PMID: 20652085 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
